UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549


FORM 10-Q/A

Amendment No. 1


[X]  Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended August 31, 2018


or


[  ]  Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.


Commission File Number: 000-54500


Cell MedX Corp.

(Exact name of registrant as specified in its charter)


Nevada

 

38-3939625

(State or other jurisdiction of

 

(I.R.S. Employer

incorporation or organization)

 

Identification No.)


123 W. Nye Ln, Suite 446

Carson City, NV

 

89706

(Address of principal executive offices)

 

(Zip code)


(844) 238-2692

(Registrant’s telephone number, including area code)



Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes [X]  No [  ]


Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or such shorter period that the registrant was required to submit and post such files).  Yes [X]  No [  ]


Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company.  See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.


Large accelerated filer  [  ]

 

Accelerated filer  [  ]

Non-accelerated filer  [  ]

 

Smaller Reporting Company [X]

 

 

Emerging Growth Company [  ]


Indicate by check mark whether the registrant is a shell company (as defined in rule 12b-2 of the Exchange Act.)  Yes [  ]  No [X]


The number of shares of the Registrant’s common stock, par value $.001 per share, outstanding as of October 15, 2018 was 44,282,749.

 




EXPLANATORY NOTE


The sole purpose of this Amendment No. 1 to Cell MedX Corp.’s Quarterly Report on Form 10-Q for the quarterly period ended August 31, 2018, originally filed with the Securities and Exchange Commission on October 15, 2018, is to file Exhibit 101 to the Form 10-Q in accordance with Rule 405 of Regulation S-T. Due to a technical error, the eXtensible Business Reporting Language (XBRL) data was not included with the initial Form 10Q filed on October 15, 2018.


No other changes have been made to the Form 10-Q. This Amendment No. 1 speaks as of the original filing date of the Form 10-Q, does not reflect events that may have occurred subsequent to the original filing date, and does not modify or update in any way disclosures made in the original filing of the Form 10-Q.



Exhibit

Number

 

Description of Document

 

 

 

31.1(1)

 

Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

 

 

 

31.2(1)

 

Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

 

 

 

32.1(1)

 

Certification of Principal Executive Officer pursuant to 18 U.S.C. 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

 

 

32.2(1)

 

Certification of Principal Financial Officer pursuant to 18 U.S.C. 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

 

 

101*

 

The following materials from this Quarterly Report on Form 10-Q for the three-month periods ended August 31, 2018 and 2017 formatted in XBRL (extensible Business Reporting Language):

 

 

(1) Consolidated Balance Sheets at August 31, 2018 (unaudited), and May 31, 2018.

 

 

(2) Unaudited Condensed Interim Consolidated Statements of Operations for the three-month periods ended August 31, 2018 and 2017.

 

 

(3) Unaudited Condensed Interim Consolidated Statement of Stockholders’ Deficit as at August 31, 2018.

 

 

(4) Unaudited Condensed Interim Consolidated Statements of Cash Flows for the Three-month Periods ended August 31, 2018 and 2017.


(1) Previously filed as an exhibit to the Form 10-Q.


* Filed herewith.














2




SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.



 

Cell MedX Corp.

 

 

Date: October 15, 2018

By:

/s/ Frank McEnulty

 

 

Frank McEnulty

 

 

Chief Executive Officer and Director

 

 

(Principal Executive Officer)

 

 

 

Date: October 15, 2018

By:

/s/Yanika Silina

 

 

Yanika Silina

 

 

Chief Financial Officer and Director

 

 

(Principal Accounting Officer)

 
































3